10-Q · May 13, 2026
Silo Pharma, Inc. reported stable revenues of $18,026,000 for Q1 2026, reflecting no growth versus Q1 2025. However, net loss increased significantly to $1,647,117, driven by a substantial rise in operating expenses and…
Earnings analysis · 10-Q
SILO earnings analysis
Filed August 13, 2026 · Our reading of the company's report
The latest report
The provided 10-Q excerpts do not include the income statement, balance sheet, cash-flow statement, segment disclosures, or MD&A, so current-quarter revenue, margins, EPS, liquidity, and cash-flow trends cannot be…
Read full summary
The provided 10-Q excerpts do not include the income statement, balance sheet, cash-flow statement, segment disclosures, or MD&A, so current-quarter revenue, margins, EPS, liquidity, and cash-flow trends cannot be quantified. The filing reports effective disclosure controls as of June 30, 2026 and no material changes to previously disclosed risk factors. Capital allocation includes a $1,000,000 repurchase authorization through December 31, 2026, but no shares were repurchased during the quarter.
Gross and operating margin
How much of each revenue dollar the business keeps.
One point per quarterly or annual filing. Both margins are shares of that report's revenue.
How we read each report
Our analysis across the last few reports.
Our model's reading of each filing, not the share price or the market's reaction. Annual and quarterly reports each occupy one position.
What stood out
-
Controls Reported Effective
Management stated that disclosure controls and procedures were effective as of June 30, 2026, with no changes during the three months ended June 30, 2026 that materially affected, or were reasonably likely to materially affect, internal control over financial reporting.
-
$1 Million Repurchase Authorization
The board authorized a common-stock repurchase program of up to $1,000,000 on February 20, 2026, remaining in place through December 31, 2026.
-
No Shares Repurchased
The company reported no repurchases during the quarterly period ended June 30, 2026, leaving the authorized program unused based on the disclosed period activity.
-
No Material Litigation Identified
The company stated it was not aware of legal proceedings or claims that would have, individually or in the aggregate, a material adverse effect on its business, financial condition, or operating results.
What to watch
-
Litigation Uncertainty
The company disclosed that litigation is subject to inherent uncertainties and that an adverse result in current or future matters could harm the business, despite stating it was not aware of proceedings with a material adverse effect.
-
Repurchase Execution Uncertain
The $1,000,000 repurchase authorization was not used during the quarter ended June 30, 2026; the filing provides no indication that repurchases will occur before the program expires on December 31, 2026.
-
Unidentified Risk Exposure
The filing states that additional risks and uncertainties not currently known or deemed immaterial could materially adversely affect the business, financial condition, or operating results.
Management's outlook
The provided 10-Q text contains no quantitative revenue or EPS outlook. No material changes to risk factors were reported versus the December 31, 2025 Form 10-K.
Earlier filings 4
10-K · March 27, 2026
Silo Pharma, Inc. reported a net loss of $4.23 million for FY 2025, an improvement compared to $4.39 million in FY 2024. The company's revenue remains stable at $72,102, driven primarily by a long-term licensing…
10-Q · November 13, 2025
For Q3 2025, Silo Pharma reported consistent revenue of $18,025, unchanged from the previous year but reflected a decline in gross margin due to increased costs. The net loss for the quarter improved slightly to $1.11…
10-Q · August 13, 2025
Silo Pharma, Inc. reported minimal revenue of $18,025 for Q2 2025, consistent with the same period in 2024, while net loss widened to $1,204,293 from a loss of $931,779 year-over-year. The company's operating expenses…
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.